Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man

References

• AMET, Y., ADAS, F. and NANJI, A. A., 1998, Fatty acid omega- and (omega-D-hydroxylation in experimental alcoholic liver disease: relationship to different dietary fatty acids. Alcoholism: Clinical and Experimental Therapeutics, 22, 1493–1500.
   Google Scholar
• ANZENBACHER, P., SOUCEK, P., ANZENBACHEROVA, E., GUT, I., HRUBY, K., SVOBODA, Z. and KVETINA, J., 1998, Presence and activity of cytochrome P450 isoforms in minipig liver. Comparison with human liver samples. Drug Metabolism and Disposition, 26, 56–59.
   PubMed Web of Science ®Google Scholar
• BOGAARDS, J. J. P., VAN OMMEN, B. and VAN BLADEREN, P. J., 1995, Human cytochrome P450 enzyme selectivities in the oxidation of chlorinated benzenes. Toxicology and Applied Pharmacology, 132, 44–52.
   Google Scholar
• BOGAARDS, J. J. P., VENEKAMP, J. C. and VAN BLADEREN, P. J., 1996, The biotransformation of isoprene and the two isoprene monoepoxides by human cytochrome P450 enzymes, compared to mouse and rat liver microsomes. Chemko-Biological Interactions, 102, 169–182.
   Google Scholar
• BOOBIS, A. R., SESARDIC, D., MURRAY, B. P., EDWARDS, R. J., SINGLETON, A. M., RICH, K. J., MURRAY, S., DE LA TORRE, R., SEGURA, J., PELKONEN, O., PASANEN, M., KOBAYASHI, S., ZHI-GUANG, T. and DAVIES, D. S., 1990, Species variation in the response of the cytochrome P-450-dependent monooxygenase system to inducers and inhibitors. Xenobiotka, 20, 1139–1161.
   Google Scholar
• BURKE, M. D., THOMPSON, S., WEAVER, R. J., WOLF, C. R. and MAYER, R. T., 1994, Cytochrome P450 specifities of alkoxyresorufin 0-dealkylation in human and rat liver. Biochemical Pharmacology, 48, 923–936.
   PubMed Web of Science ®Google Scholar
• CHANG, T. K. H., GONZALEZ, F. J. and WAXMAN, D. J., 1994, Evaluation of triacetyloleandomycin, a-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochrome P450. Archives of Biochemistry and Biophysics, 311, 437–442.
   Google Scholar
• CHOLERTON, S., DALY, A. K. and IDLE, J. R., 1992, The role of individual human cytochromes P450 in drug metabolism and clinical response. TiPS Reviews, 13, 434–439.
   PubMed Web of Science ®Google Scholar
• DALY, A. K., CHOLERTON, S., GREGORY, W. and IDLE, J. R., 1993, Metabolic Polymorphisms. Pharmacology and Therapeutics, 57, 129–160.
   PubMed Web of Science ®Google Scholar
• DANIEL, H. I. and EDEKI, T. I., 1996, Genetic polymorphism of S-mephenytoin 4'-hydroxylation. Psychopharmacology Bulletin, 32, 219–230.
   PubMed Web of Science ®Google Scholar
• DIRVEN, H. A. A. M., BRULIN, A. A. G. M. DE, SESSINK, P. J. M. and JONGENEELEN, F. J., 1991, Determination of the cytochrome P450 4 marker, th-hydroxylauric acid by high performance liquid chromatography and fluorometric detection. Journal of Chromatography, 564,266–271.
   Google Scholar
• EAGLING, V. A., TIIA, J. F. and BACK, D., 1998, Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. British Journal of Clinical Pharmacology, 45, 107–114.
   PubMed Web of Science ®Google Scholar
• FORRESTER, L. M., HENDERSON, C. J., GLANCEY, M. J., BACK, D. J., PARK, B. K., BALL, S. E., KITTERINGHAM, N. R., MCLAREN, A. W., MILES, J. S., SKETT, P. and WOLF, C. R., 1992, Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochemical Journal, 281, 359–368.
   PubMed Web of Science ®Google Scholar
• FURUYA, H., FERNANDEZ-SALGUERO, P., GREGORY, W., TABER, H., STEWARD, A., GONZALEZE, F. J. and IDLE, J. R., 1995, Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics, 5, 389–392.
   Google Scholar
• GHOSAL, A., SATOH, H., THOMAS, P. E., BusH, E. and MOORE, D., 1996, Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metabolism and Disposition, 24, 940–947.
   PubMed Web of Science ®Google Scholar
• GONZALEZ, F. J. and IDLE, J. R., 1994, Pharmacogenetic phenotyping and genotyping. Clinical Pharmacokinetics, 26, 59–70.
   PubMed Web of Science ®Google Scholar
• GONZALEZ, F. J. and GELBOIN, H. V.,1994, Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metabolism Reviews, 26, 165–183.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1990, Mechanism-based inactivation of human liver microsomal cytochrome P450 IIIA4 by gestodine. Chemical Research in Toxicology, 3, 363–371.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1991, Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chemical Research in Toxicology, 4, 391–407.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1997, Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chemico-Biological Interactions, 106, 161–182.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., KIM, D. and IwAsmu, M., 1991, Role of human cytochrome P-450 11E1 in the oxidation of many low molecular weight cancer suspects. Chemical Research in Toxicology, 4, 168–179.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P. and SHIMADA, T., 1991, Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chemical Research in Toxicology, 4, 391–407.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P. and TURVEY, C. G., 1991, Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immuno - chemical analysis of surgical liver samples. Journal of Pharmacology and Experimental Thera-peutics, 256, 1189–1194.
   PubMed Web of Science ®Google Scholar
• HONKAKOSHI, P. and NEGISHI, M., 1997, The structure, function and regulation of cytochrome P450 2A enzymes. Drug Metabolism Reviews, 29, 977–996.
   PubMed Web of Science ®Google Scholar
• KATO, R. and YAMAZOE, Y., 1992, Sex-specific cytochrome P450 as a cause of sex- and species-related differences in drug toxicity. Toxicology Letters, 64/65, 661–667.
   Google Scholar
• KIMONEN, T., JUVONEN, R. O., ALHAVA, E. and PASANEN, M., 1995, The inhibition of CYP enzymes in mouse and human liver by pilocarpine. British Journal of Pharmacology, 114, 832–836.
   PubMed Web of Science ®Google Scholar
• KUNZE, K. L. and TRAGER, W. F., 1993, Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chemical Research in Toxicology, 6, 649–656.
   PubMed Web of Science ®Google Scholar
• LEWIS, D. F. V., LAJE, B. G., DICKINS, M., EDDERSHAW, P. J., TARBIT, M. H. and GOLDFARB, P. S., 1999, Molecular modelling of CYP2B6, the human CYP2B isoform, by homology with the substrate-bound CYP102 crystal structure: evaluation of CYP2B6 substrate characteristics, the cytochrome b, binding site and comparisons with CYP2B1 and CYP2B4. Xenobiotica, 29, 361–393.
   Google Scholar
• LINDBERG, R. L. and NEGISHI, M., 1989, Alteration of mouse cytochrome P450,0„ substrate specificity by mutation of a single amino-acid residue. Nature, 339, 632–634.
   PubMed Web of Science ®Google Scholar
• LUCAS, D., BERTHOU, F., DRANO, Y., LOZAC'H, P., VOLANT, A. and NUNEZ, J., 1993, Comparison of levels of cytochromes P-450, CYP1A2, CYP2E1, and their related monooxygenase activities in human surgical samples. Alcoholism: Clinical and Experimental Research, 17, 900–905
   Google Scholar
• MAKOWSKA, J. M. and GIBSON, G. G., 1992, Species differences in cipofibrate induction of hepatic cytochrome P450 4A1 and peroxisome proliferation. Journal of Biochemical Toxicology, 7, 183–191.
   PubMedGoogle Scholar
• NAGATA, K., GONZALEZ, F. J., YAMAZOE, Y. and KATO, R., 1990, Purification and characterization of four catalytically active testosterone 6/4-hydroxylase P-450s from rat liver microsomes : comparison of a novel form with three structurally and functionally related forms. Journal of Biochemistry, 107, 718–725.
   PubMed Web of Science ®Google Scholar
• NAKACHI, K., ImAI, K., HAYASHI, S. and KAWAJIRI, K., 1993, Polymorphisms of the CYP1A1 and glutathione S-transfera genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Research, 53, 2994–2999.
   PubMed Web of Science ®Google Scholar
• NELSON, D. R., KAMATAKI, T., WAXMAN, D. J., GUENGERICH, F. P., ESTABROOK, R. W., FEYEREISEN, R., GONZALEZ, F. J., COON, M. J., GUNSALUS, I. C., GOTOH, O., OKUDA, K. and NEBERT, D. W., 1993, The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA and Cell Biology, 12, 1–51.
   PubMed Web of Science ®Google Scholar
• NELSON, D. R., KOYMANS, L., KAMATAKI, T., STEGEMAN, J. J., FEYEREISEN, R., WAXMAN, D. J., WATERMAN, M. R., GOTOH, O., COON, M. J., ESTABROOK, R. W., GUNSALUS, I. C. and NEBERT, D. W., 1996, P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetks, 6, 1–42.
   PubMedGoogle Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y. H., 1995, Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• OHMORI, S., TANIGUCHI, T., RIKIHISA, T., KANAKUBO, Y. and KITADA, M., 1993, Species differences of testosterone 16-hydroxylase in liver microsomes of guinea pig, rat and dog. Xenobiotica, 23, 419426.
   Web of Science ®Google Scholar
• ONO, S., HATANAKA, T., HOTTA, H., SATOH, T., GONZALEZ, F. J. and TSUTSUI, M., 1996, Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica, 26, 681–693.
   PubMed Web of Science ®Google Scholar
• PEARCE, R., GREENWAY, D. and PARKINSON, A., 1992, Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. Archives of Biochemistry and Biophysics, 298, 211–225.
   PubMed Web of Science ®Google Scholar
• PERELLA, F. W., 1988, EZ-FIT : a practical curve-fitting microcomputer program for the analysis of enzyme kinetic data on IBM-PC compatible computers. Analytical Biochemistry, 174, 437–447.
   PubMed Web of Science ®Google Scholar
• POWELL, P. K., WOLF, I. and LASKER, J. M., 1996, Identification of CYP4A11 as the major lauric acid omega-hydroxylase in human liver microsomes. Archives of Biochemistry and Biophysics, 335, 219–226.
   PubMed Web of Science ®Google Scholar
• SCHMIDER, J., GREENBLATT, D. J., MOLTKE, L. L. VON, HARMATZ, J. S., DUAN, S. X., KARSOV, D. and SHADER, R. I., 1996, Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. Pharmacology, 52, 125–134.
   Google Scholar
• SHARER, J. E., SHIPLEY, L. A., VANDERBRANDEN, M. R., BINKLEY, S. N. and WRIGHTON, S. A., 1995, Comparisons of phase land phase II in vitro enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metabolism and Disposition, 23, 1231–1241.
   PubMed Web of Science ®Google Scholar
• SHARMA, R., LAKE, B. G., FOSTER, J. and GIBSON, G. G., 1988, Microsomal cytochrome P452 induction and peroxisome proliferation by hypolipidaemic agents in liver. A mechanistic inter-relationship. Biochemical Pharmacology, 37, 1193–1201.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with human liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
   PubMed Web of Science ®Google Scholar
• STEVENS, J. C., SHIPLEY, L. A., CASHMAN, J. R., VANDENBRANDEN, M. and WRIGTHON, S. A., 1993, Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities. Drug Metabolism and Disposition, 21, 753–760.
   PubMed Web of Science ®Google Scholar
• TOMLINSON, E. S., MAGGS, J. J., PARK, B. K., AND BACK, D. J., 1997, Dexamethasone metabolism in vitro: species differences. Journal of Steroid Biochemistry and Molecular Biology, 62, 345–352.
   PubMed Web of Science ®Google Scholar
• WEAVER, R. J., DICKINS, M. and BuRKE, M. D., 1999, A comparison of basal and induced hepatic microsomal cytochrome P450 monooxygenase activities in cynomolgus monkey (Macaca fascicularis) and man. Xenobiotica, 29, 467–482.
   PubMed Web of Science ®Google Scholar
• WEAVER, R. J., THOMPSON, S., SMITH, G., DICKINS, M., ELCOMBE, C. R., MAYER, R. T. BURKE, M. D., 1994, A comparative study of constitutive and induced alkoxyresorufin 0-dealkylation and individual cytochrome P450 forms in cynomolgus monkey (Macaca fascicularis), human, mouse, rat and hamster liver microsomes. Biochemical Pharmacology, 47, 763–773.
   PubMed Web of Science ®Google Scholar
• WERNER, M., BIRNER, G. and DEKANT, W., 1995, The role of cytochrome P4503A1/2 in the sex-specific sulfoxidation of the hexachlorobutadiene metabolite, N-acetyl-S-(pentachlorobutadieny1)- L-cysteine in rats. Drug Metabolism and Disposition, 23, 861–868.
   PubMed Web of Science ®Google Scholar
• WRIGHTON, S. A. and RING, B. J., 1994, Inhibition of human CYP3A catalyzed by 1'-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharmaceutical Research, 6, 921–924.
   Web of Science ®Google Scholar
• WRIGHTON, S. A. and STEVENS, J. C., 1992, The human hepatic cytochromes P450 involved in drug metabolism. Critical Reviews in Toxicology, 22, 1–21.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H., MIMURA, M., SUGAHARA, C. and SHIMADA, T., 1994, Catalytic roles of rat and human cytochrome P450 2A enzymes in testosterone 7- and coumarin 7-hydroxylations. Biochemical Pharmacology, 48,1524–1527.
   PubMed Web of Science ®Google Scholar
• YASUMORI, T., CHEN, L., NAGAT, K., YAMAZOE, Y. and KATO, R., 1993, Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3 A). journal of Pharmacology and Experimental Therapeutics, 264, 89–94.
   PubMed Web of Science ®Google Scholar